Large Cystic Lung Mass Found in 3-Year-Old Boy

Poll

A large cystic lung mass is found in the right upper lobe of a 3-year-old boy. After further evaluation, a biopsy is performed. What is your diagnosis?

A large cystic lung mass is found in the right upper lobe of a 3-year-old boy. According to the histopathology image below, what is your diagnosis?

What is your diagnosis?

A. Bronchioloalveolar carcinoma
B. Cystic adenomatoid malformation
C. Pleuropulmonary blastoma
D. Bronchogenic cyst
Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
Related Content
End-of-life demands card game and mindfulness-based cancer recovery program use may enhance the quality of life for patients with lung cancer.

Mindfulness/Activity Program May Ease Anxiety Over Death from Lung Cancer

Roman Fabbricatore
April 19th 2025
Article

End-of-life demands card game and mindfulness-based cancer recovery program use may enhance the quality of life for patients with lung cancer.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC

Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC

Tim Cortese
April 18th 2025
Article

Pooled results from the TRUST-I and TRUST-II trials showed that taletrectinib led to infrequent neurological TEAEs in patients with ROS1-positive NSCLC.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Surufatinib/Toripalimab Shows Encouraging Activity in NSCLC and SCLC

Surufatinib/Toripalimab Shows Encouraging Activity in NSCLC and SCLC

Tim Cortese
April 8th 2025
Article

Surufatinib/toripalimab elicited an ORR of 57.1% in patients with treatment-naïve NSCLC and 15.8% in patients with pretreated SCLC in a phase 2 trial.

A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.

Developers Terminate Clinical Program for Ociperlimab in Lung Cancer

Russ Conroy
April 3rd 2025
Article

A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.